ACT Capital Management’s Krystal Biotech KRYS Stock Holding History

ACT Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.7M	Sell	45,000 -15,477	-26%	-$4.62M	10.93%	1
2026 Q1	$15.6M	Sell	60,477 -23	-0%	-$6.12K	12.28%	1
2025 Q4	$14.9M	Buy	+60,500	New	+$12.7M	12.06%	1
2022 Q3	$4.06M	Sell	58,300 -700	-1%	-$50.6K	5.61%	4
2022 Q2	$3.87M	Hold	59,000	–	–	5.42%	5
2022 Q1	$3.93M	Hold	59,000	–	–	4.15%	6
2021 Q4	$4.13M	Buy	59,000 +19,000	+48%	+$1.11M	2.98%	6
2021 Q3	$2.09M	Buy	40,000 +20,925	+110%	+$1.24M	1.08%	18
2021 Q2	$1.3M	Buy	+19,075	New	+$1.33M	0.67%	33

Other funds holding KRYS

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PIP

Palisades Investment Partners Santa Monica, California $352M AUM 76.79% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

ACT Capital Management's KRYS Position: Q2 2026 in Review

ACT Capital Management reduced its Krystal Biotech (KRYS) stake by 26% in Q2 2026, selling an estimated $4.62M and leaving 45,000 shares worth $16.7M. The position accounts for 10.93% of the portfolio, ranked #1.

ACT Capital Management first reported a position in KRYS in Q2 2021 and has held it in 9 quarters since. 151 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

ACT Capital Management held 45,000 shares of Krystal Biotech worth $16.7M as of Q2 2026.
ACT Capital Management sold 15,477 Krystal Biotech shares in Q2 2026, an estimated $4.62M.
Krystal Biotech made up 10.93% of ACT Capital Management's portfolio in Q2 2026, its #1 holding.
ACT Capital Management first reported a position in Krystal Biotech in Q2 2021 and has held it in 9 quarters since.
151 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.